1 / 20

Lymphatic Filiriasis:

Lymphatic Filiriasis:. A Case Report John W. Hariadi , M.D. Emory Family Medicine. History. 35 yo BF with 10 year hx of LLE swelling & foot deformity -Swelling first started 10-12 years ago, initially involving entire leg up to her groin, with “hardening” of the skin

troy-lester
Télécharger la présentation

Lymphatic Filiriasis:

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Lymphatic Filiriasis: A Case Report John W. Hariadi, M.D. Emory Family Medicine

  2. History 35 yo BF with 10 year hx of LLE swelling & foot deformity -Swelling first started 10-12 years ago, initially involving entire leg up to her groin, with “hardening” of the skin -Over the years, swelling subsided some except for L foot deformity -She can ambulate, denies pain -Denies F/C, constitutional sxs -No meds or allergies -Lived her entire life in Buenaventura, Colombia -PMH: Malaria in past, o/w negative -SH: Single –”No one wants to marry me because of my foot”, lives with mother & sister’s family. No T/E/D -FH: Unremarkable Elevation: 49FT Latitude: 3 58 N Longitude: 77 18W

  3. Buenaventura, Colombia

  4. Physical • Vital Signs WNL • LLE: Significant edema from groin distal to her foot (WHO-Grade III) • World Health Organization Grading Classification: • Grade I: Pitting edema reversible by elevation • Grade II: Nonpitting edema, not reversible by elevation • Grade III: Severe swelling with sclerosis and skin changes • L foot severely deformed with complete loss of definition of her toes • Skin warm, w/o erythema, induration, ecchymoses • Entire LE nontender to palpation with FROM of her knee and ankle (dorsiflexion and plantarflexion)

  5. Radiograph

  6. Diagnostic Testing • Urinalysis, CBC and Comprehensive Chemistries WNL • Foot Biopsy: Normal Skin with areas of chronic inflammation • Blood examination for microfilariae was negative, but serology for IgG4 antibodies was positive for Wuchereria bancrofti

  7. Treatment • One time combination therapy of diethylcarbamazine (DEC) and albendazole • Unlikely to reverse her condition due to chronic nature of disease and fibrosis of lymphatics • May kill any viable adult worms and diminish parasite load

  8. Force Protection • Anchorage Security • Shipboard Security Team • 200 yd exclusion zone • 2 armed picket boats • Explosive integrity check inspection area • Fleet Landing Security • Integrity checks • Pier Security Team • 100% vehicle and baggage check • 400 ft standoff radius • Barriers • MEDCAP Security • Armed HN Security Force at site and in transit • 100 yd exclusion zone for helo POC: STGCS Pageau

  9. Lymphatic Filiarisis • Caused by infection with one of 3 nematodes: • Wuchereria bancrofti • Brugia malayi • Brugia timori • 120 million people worldwide are infected, 90% due to W. bancrofti. • W. bancrofti endemic in subsaharan Africa, SE Asia, Indian subcontinent, many Pacific Islands and Greater Amazon Basin • 40 million people disfigured, severely incapacitated • Studies from India (40% of worldwide cases) • 29 days of work lost/year • >$ 843 million due to treatment costs and lost working days • Heavy Social Burden: issues with marriage

  10. Epidemiology • W. bancrofti acquired via bite of mosquitoes • Numerous species can serve as vectors: • Anopheles, Culex, Aedes, Mansonia • Prevalence increasing due to urbanization, increased breeding sites for mosquito vectors

  11. Life Cycle • Larva deposited by mosquito bite • Travel through dermis to lymphatic vessels • Growth (approx 9 months) to mature worms(20-100mm long) • Worms live 5-7 years (occasionally up to15 years) • Mate->Microfilariae (1st stage larva) • Females->release up to 10,000 microfilariae/day into bloodstream • Microfilarie taken up by mosquito bite • Develop into 2nd and 3rd stage larva over 10-14 days inside mosquito vector Hospital

  12. Life Cycle

  13. Clinical Course • Initially asymptomatic • Symptoms develop with increasing numbers of worms • Less than 1/3 of infected individuals have acute symptoms • Clinical Course is 3 phases: • Asymptomatic Microfilaremia • Acute Adenolymphangitis (ADL) • Chronic/Irreversible lymphedema • Superimposed upon repeated episodes of ADL

  14. Acute ADL • Presents with sudden onset of fever and painful lymphadenopathy • Retrograde Lymphangitis • Inflammation spreads distally away from lymph node group • Immune mediated response to dying worms • Most common areas: Inguinal nodes and Lower extremities • Inflammation spontaneously resolve after 4-7 days but can recur frequently • Recurrences usually 1-4 times/year with increasing severity of lymphedema • Secondary bacterial infections in edematous(elephantatic) areas • Filarial fever (fever w/o lymphangitis) • Tropical Pulmonary Eosinophilia • Nocturnal Wheezing (young males) • Hyperresponsiveness to microfilariae trapped in lungs

  15. Chronic Manifestations • Lymphedema • Mostly LE and inguinal, but can affect UE and breast • Initially pitting edema, with gradual hardening of tissues hyperpigmentation & hyperkeratosis • GenitaliaHydroceles • Renal involvement • Chylurialymph discharge into urine • Loss of fat and protein hypoproteinemia & anemia • Hematuria, proteinuria from ?immune complex nephritis • Secondary bacterial/fungal infections

  16. Diagnosis • Mainly Clinical • Eosinophilia, which may exceed 3000/ml • Microscopic hematuria, proteinuria, chyluria may be present • Blood smear for Microfiliariae with Giemsa or Wright’s stains • Blood drawn between 10pm-2am • Serological Testing: • Antifilaria Antibodies (IgG,IgG4,IgE) • IgG4 has 96% sensitivity • Circulating Filarial Antigens (CFA) • ELISA of Og4C3 CFA has 99% sensitivity & specificity • Negative within 12 months of curative treatment • Can be used to follow pts • Becoming gold standard Hotel Estacion

  17. Diagnosis • Ultrasound • Can be used to detect motion of adult worms • Can monitor effectiveness of drug therapy • Contrast Lymphangiography • Can directly visualize lymphatic vessels • Potential risk of causing lymph damage Alvaro Uribe Brian Nichols

  18. Treatment • Drug of Choice is single initial dose of Diethylcarbamazine (DEC) • Dosage 6mg/kg, with possible repeat dose in 6 months • Sustained 90-99% reduction in microfilaremia for at least 1 yr • SEs include fever, headache, anorexia, nausea and arthralgias • SEs not due to drug itself but host response following damage to adult worms and microfilariaerelease of lipopolysaccharide-like proteins from endosymbiotic Wolbachia organisms present within filariae • Symptoms can be treated with antipyretics/anti inflammatory agents • Ivermectin • Albendazole • Combination therapy: DEC & Albendazole has best efficacy92-99% reduction in intensity of microfilariae after 1 year, >75% reduction in annual transmission

  19. Alternate TreatmentStrategies • Attacking the Wolbachia (intracellular bacterial symbiont of worms) • Worms need Wolbachia to mate and reproduce • Doxycycline has good activity against Wolbachia • Tanzanian studies: Combination of 3 weeks of doxycycline followed by DEC/ivermectin /albendazole was efficaceous in reducing microfilarie load • Doxycyline is cheap and well-tolerated, pretreatment prior to DEC shown in small studies to reduce SEs of treatment because of lower Wolbachia load • Community based programs • WHO has ongoing Global initiative to fight lymphatic filiarisis • Massed Administration of medication in endemic areas • Community education programs to raise awareness, promote local hygiene and control mosquito vector populations

More Related